Urolithin A analog inhibits castration-resistant prostate cancer by targeting the androgen receptor and its variant, androgen receptor-variant 7

• Main Authors: Balaji Chandrasekaran (Author), Ashish Tyagi (Author), Uttara Saran (Author), Venkatesh Kolluru (Author), Becca V. Baby (Author), Venkat R. Chirasani (Author), Nikolay V. Dokholyan (Author), Jyh M. Lin (Author), Amandeep Singh (Author), Arun K. Sharma (Author), Murali K. Ankem (Author), Chendil Damodaran (Author)
• Format: Book
• Published: Frontiers Media S.A., 2023-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

We investigated the efficacy of a small molecule ASR-600, an analog of Urolithin A (Uro A), on blocking androgen receptor (AR) and its splice variant AR-variant 7 (AR-V7) signaling in castration-resistant prostate cancer (CRPC). ASR-600 effectively suppressed the growth of AR+ CRPC cells by inhibiti...